Viatris
53 articles with Viatris
-
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors
12/29/2022
Viatris Inc., a global healthcare company, announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris' newest members of its board of directors.
-
Viatris Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference
12/23/2022
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11 , 2023.
-
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan
12/13/2022
Calliditas Therapeutics AB announced that they have entered into an exclusive license agreement with Viatris Pharmaceuticals Japan Inc., a subsidiary of Viatris Inc., to register and commercialize Nefecon, a specialty drug recently approved in Europe and the US for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy in Japan.
-
Biocon Biologics Completes Acquisition of Viatris' Global Biosimilars Business
11/29/2022
Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), announced that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS).
-
Viatris Completes Biosimilars Transaction with Biocon Biologics
11/29/2022
Viatris Inc. announced that it has closed its transaction with Biocon Biologics Limited, creating what Viatris expects to be a unique fully vertically integrated global biosimilars leader.
-
Viatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences
11/18/2022
Viatris Inc . (NASDAQ: VTRS), a global healthcare company, today announced that it has been named the winner in three categories at the 10th annual LMG Life Sciences 2022 Americas Awards.
-
Viatris Reports Strong Third Quarter 2022 Results
11/7/2022
Viatris Inc. (NASDAQ: VTRS) today reported strong results for the third quarter of 2022 and reaffirmed its 2022 financial guidance.
-
Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event
11/7/2022
Viatris Inc. announced that it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences and that it will provide a strategic update on its February 2022 Investor Event in a conference call and live webcast today at 8:30 a.m. ET.
-
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
11/7/2022
Oyster Point Pharma, Inc., announced that it has entered into a definitive agreement under which Viatris Inc., a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
-
Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022
10/24/2022
Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022.
-
Viatris Named to Forbes' Annual List of the World's Best Employers for the Second Year in a Row
10/11/2022
Viatris Inc., a global pharmaceutical company, announced that it has been named to Forbes' list of World's Best Employers 2022.
-
The HHS Office of Inspector General found that of 278 accelerated approvals between 1992 and 2021, 104 had incomplete confirmatory trials, according to a report issued Thursday.
-
This week had a flurry of biopharma patent cases, from Novartis vs Gilenya, Merck vs Viatris, and Aligos vs Janssen, either filed or court decisions being made.
-
Viatris Inc. to Participate in BofA Global Research Global Healthcare Conference
9/6/2022
Viatris Inc., a global pharmaceutical company, announced the company will participate in the BofA Global Research Global Healthcare Conference in London on Thursday, September 15, 2022.
-
Viatris Reports Strong Second Quarter 2022 Results
8/8/2022
Viatris Inc. (NASDAQ: VTRS) today reported strong results for the second quarter of 2022 and provided an update to its full year 2022 financial guidance.
-
Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022
7/1/2022
Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial markets.
-
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
-
Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
5/20/2022
Viatris Inc., a global pharmaceutical company, announced the company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, CA on Tuesday, June 14, 2022.
-
Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals
5/16/2022
Viatris Inc. published its 2021 Sustainability Report, outlining the company's 2021 achievements and progress across key areas including Access and Global Health, Employees, Environmental Stewardship and Community Engagement and including details on Viatris' continued efforts to support employees and their families while maintaining a stable supply of medicines during the ongoing COVID-19 pandemic.
-
Viatris Reports Strong First-Quarter 2022 Results
5/9/2022
Viatris Inc. (NASDAQ: VTRS), today reported strong results for the first quarter of 2022.